Founded in 2005 in Pirmasens, Germany, Cytoimmun Diagnostics GmbH is the world's technological leader in prognostic markers when it comes to HPV-triggered cervical carcinomas and their precursors.
The L1 capsid detection method, medically approved and awarded several times, is known worldwide under the name "Cytoactiv®" lab test". For the first time, it is made possible to predict the further course of conspicuous cell changes on the cervix with an 80% certainty.
The Cytoactiv® test represents a revolution: Before, women diagnosed with cervical intraepithelial neoplasia or squamous intraepithelial lesions (LSIL) had to worry for months whether the human papillomavirus infection would heal on its own or whether surgery (conization) would be necessary. A nagging uncertainty for patients and an extremely unsatisfactory situation for gynecologists - with the "game changer" - the Cytoactiv® lab test - this is finally a thing of the past.
Therefore, our mission is:
Gynecologists, pathologists, laboratory physicians and cytologists trust us.